Literature DB >> 25323658

Differentiated thyroid cancer patients with a previous indeterminate (Thy 3) cytology have a better prognosis than those with suspicious or malignant FNAC reports.

Pierpaolo Trimboli1, Massimo Bongiovanni, Fabio Rossi, Leo Guidobaldi, Anna Crescenzi, Luca Ceriani, Giuseppe Nigri, Stefano Valabrega, Francesco Romanelli, Luca Giovanella.   

Abstract

The prognosis of differentiated thyroid cancers (DTC) read at cytology as indeterminate and classified as Thy 3 according to the British Thyroid Association has recently been suggested to be good. To obtain robust information about this potential novelty, in this study we retrospectively reviewed DTC with a prior fine-needle aspiration cytology (FNAC) of Thy 3, Thy 4 or Thy 5 presently followed up at two institutes. Patients with no FNAC before surgery were excluded and a series of 284 DTC was enrolled in the study. Of these, 53 had Thy 3, 108 Thy 4, and 123 had Thy 5 prior to surgery. At histology, 280 (98.6 %) papillary and 4 follicular (1.4 %) cancers were found. Overall, the less aggressive cancer forms were prevalent in all three groups. The lower TNM stages (I and II) were more frequent in the Thy 3 group (96.2 %) than in the other cases (76.6 %) (p < 0.001). Neck lymph node metastasis at diagnosis was found in 3.8 % of Thy 3, 18.5 % of Thy 4, and 26 % of Thy 5 cases. At follow-up, a 16.2 % recurrence rate was recorded, ranging from 1.9 % in Thy 3 group to 19.5 % for Thy 4 and Thy 5 (p < 0.001). According to the Kaplan-Meier curve, Thy 3 was thus a favorable prognostic factor compared with Thy 4 and Thy 5 (OR = 0.079, p < 0.001, 95 %CI 0.01-0.59). At multivariate analysis, Thy 3 was an independent predictor of good prognosis (OR = 0.06, p = 0.03, 95 %CI 0.01-0.80). In conclusion, DTC with a preoperative Thy 3 cytology have a better prognosis than those with Thy 4 and Thy 5 due to less aggressive tumor types and lower TNM stage at diagnosis.

Entities:  

Mesh:

Year:  2014        PMID: 25323658     DOI: 10.1007/s12020-014-0453-1

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  16 in total

Review 1.  Clinical and ultrasound parameters in the approach to thyroid nodules cytologically classified as indeterminate neoplasm.

Authors:  Pierpaolo Trimboli; Emma Condorelli; Antonio Catania; Salvatore Sorrenti
Journal:  Diagn Cytopathol       Date:  2009-10       Impact factor: 1.582

2.  The Bethesda System for Reporting Thyroid Cytopathology.

Authors:  Edmund S Cibas; Syed Z Ali
Journal:  Thyroid       Date:  2009-11       Impact factor: 6.568

3.  Increasing incidence of thyroid cancer in the United States, 1973-2002.

Authors:  Louise Davies; H Gilbert Welch
Journal:  JAMA       Date:  2006-05-10       Impact factor: 56.272

4.  Thyroid nodules with indeterminate cytology: molecular imaging with ⁹⁹mTc-methoxyisobutylisonitrile (MIBI) is more cost-effective than the Afirma gene expression classifier.

Authors:  Alexander Heinzel; Dirk Müller; Florian F Behrendt; Luca Giovanella; Felix M Mottaghy; Frederik A Verburg
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-04-05       Impact factor: 9.236

Review 5.  Thyroid carcinoma.

Authors:  Steven I Sherman
Journal:  Lancet       Date:  2003-02-08       Impact factor: 79.321

6.  Thin core biopsy should help to discriminate thyroid nodules cytologically classified as indeterminate. A new sampling technique.

Authors:  Naim Nasrollah; Pierpaolo Trimboli; Leo Guidobaldi; Davide Domenico Cicciarella Modica; Claudio Ventura; Giovanni Ramacciato; Silvia Taccogna; Francesco Romanelli; Stefano Valabrega; Anna Crescenzi
Journal:  Endocrine       Date:  2012-10-16       Impact factor: 3.633

Review 7.  Well differentiated thyroid cancer.

Authors:  Barbara K Kinder
Journal:  Curr Opin Oncol       Date:  2003-01       Impact factor: 3.645

Review 8.  The demise of follicular carcinoma of the thyroid gland.

Authors:  V A LiVolsi; S L Asa
Journal:  Thyroid       Date:  1994       Impact factor: 6.568

9.  Galectin-3-expression analysis in the surgical selection of follicular thyroid nodules with indeterminate fine-needle aspiration cytology: a prospective multicentre study.

Authors:  Armando Bartolazzi; Fabio Orlandi; Enrico Saggiorato; Marco Volante; Federico Arecco; Ruth Rossetto; Nicola Palestini; Ezio Ghigo; Mauro Papotti; Gianni Bussolati; Marco Paolo Martegani; Federico Pantellini; Angelo Carpi; Maria Rosaria Giovagnoli; Salvatore Monti; Vincenzo Toscano; Salvatore Sciacchitano; Gian Maria Pennelli; Caterina Mian; Maria Rosa Pelizzo; Massimo Rugge; Giancarlo Troncone; Lucio Palombini; Gennaro Chiappetta; Gerardo Botti; Aldo Vecchione; Rino Bellocco
Journal:  Lancet Oncol       Date:  2008-05-19       Impact factor: 41.316

10.  The large majority of 1520 patients with indeterminate thyroid nodule at cytology have a favorable outcome, and a clinical risk score has a high negative predictive value for a more cumbersome cancer disease.

Authors:  Teresa Rago; Maria Scutari; Francesco Latrofa; Valeria Loiacono; Paolo Piaggi; Ivo Marchetti; Rossana Romani; Fulvio Basolo; Paolo Miccoli; Massimo Tonacchera; Paolo Vitti
Journal:  J Clin Endocrinol Metab       Date:  2014-04-07       Impact factor: 5.958

View more
  9 in total

1.  A cost analysis of thyroid core needle biopsy vs. diagnostic surgery.

Authors:  Pierpaolo Trimboli; Naim Nasrollah; Stefano Amendola; Anna Crescenzi; Leo Guidobaldi; Carlo Chiesa; Riccardo Maglio; Giuseppe Nigri; Alfredo Pontecorvi; Francesco Romanelli; Laura Giacomelli; Stefano Valabrega
Journal:  Gland Surg       Date:  2015-08

2.  Galectin-3 and HBME-1 improve the accuracy of core biopsy in indeterminate thyroid nodules.

Authors:  Pierpaolo Trimboli; Leo Guidobaldi; Stefano Amendola; Naim Nasrollah; Francesco Romanelli; Daniela Attanasio; Giovanni Ramacciato; Enrico Saggiorato; Stefano Valabrega; Anna Crescenzi
Journal:  Endocrine       Date:  2015-07-04       Impact factor: 3.633

3.  Retrospective cytological evaluation of indeterminate thyroid nodules according to the British Thyroid Association 2014 classification and comparison of clinical evaluation and outcomes.

Authors:  Massimo Giusti; Barbara Massa; Margherita Balestra; Paola Calamaro; Stefano Gay; Simone Schiaffino; Giovanni Turtulici; Simonetta Zupo; Eleonora Monti; Gianluca Ansaldo
Journal:  J Zhejiang Univ Sci B       Date:  2017-07       Impact factor: 3.066

4.  Association of Tumor Size With Histologic and Clinical Outcomes Among Patients With Cytologically Indeterminate Thyroid Nodules.

Authors:  Pablo Valderrabano; Laila Khazai; Zachary J Thompson; Kristen J Otto; Julie E Hallanger-Johnson; Christine H Chung; Barbara A Centeno; Bryan McIver
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2018-09-01       Impact factor: 6.223

Review 5.  How to handle borderline/precursor thyroid tumors in management of patients with thyroid nodules.

Authors:  Kennichi Kakudo
Journal:  Gland Surg       Date:  2018-08

6.  Gene expression classifier for the diagnosis of indeterminate thyroid nodules: a meta-analysis.

Authors:  Prasanna Santhanam; Rodhan Khthir; Todd Gress; Ayman Elkadry; Omolola Olajide; Abid Yaqub; Henry Driscoll
Journal:  Med Oncol       Date:  2016-01-09       Impact factor: 3.064

Review 7.  Galectin-3 Performance in Histologic a Cytologic Assessment of Thyroid Nodules: A Systematic Review and Meta-Analysis.

Authors:  Pierpaolo Trimboli; Camilla Virili; Francesco Romanelli; Anna Crescenzi; Luca Giovanella
Journal:  Int J Mol Sci       Date:  2017-08-11       Impact factor: 5.923

8.  Reliability of core needle biopsy as a second-line procedure in thyroid nodules with an indeterminate fine-needle aspiration report: a systematic review and meta-analysis.

Authors:  Pierpaolo Trimboli; Luca Giovanella
Journal:  Ultrasonography       Date:  2018-01-02

9.  Thyroid nodules with indeterminate cytology: association between nodule size, histopathological characteristics and clinical outcome in differentiated thyroid carcinomas - a multicenter retrospective cohort study on 761 patients.

Authors:  Federico Cozzani; Dario Bettini; Matteo Rossini; Elena Bonati; Simona Nuzzo; Tommaso Loderer; Giuseppe Pedrazzi; Alberto Zaccaroni; Paolo Del Rio
Journal:  Updates Surg       Date:  2021-06-07
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.